Circle 4: How the Interface Between Physicians and Industry has Changed

PRESENTED BY: ADELAIDE A. HEBERT, MD
AND KATHLEEN HECTORNE, MD
Robust and unrestricted interchange between industry and physicians for many years
Changes

Pharmaceutical Representatives:
- Who can see them
- Where
- Why

Impact of those changes
Early Changes

- Separation of Marketing from Research and Development

- Use of Regional Scientific Liasons for:
  - Scientific Inquiries
  - Investigator Initiated Research
Physicians Payments Sunshine Act

- Data collection began August 2013
- Public Reporting 2014:
- Under the National Physician Payment Transparency Program of the Centers for Medicare and Medicaid Services
Financial Relationships Between Physicians and Industry

- 2007 report: 94% of physicians had relationships
- 83% received gifts
- 28% received payment for professional services such as consulting and research participation
- 60% of those 28% were involved in medical education
- 40% of those 28% were involved in creating clinical practice guidelines

Financial Relationships between Physicians and Industry

- By 2001 industry = major source of research and development funding
- 60% of 100 billion dollars in funding annually
- One third of all CME
Payments Requiring Reporting: The Sunshine Act

- Transactions of $10 or more
- Transactions under $10 if they total $100 in a calendar year
Payments Requiring Reporting: The Sunshine Act

- Teaching hospitals must also report payments
Private Practitioners

- Can see sales representatives in their offices
- Allow lunches for physicians and staff
- Accept samples
- Can use branded pharmaceutical aids / signs / pamphlets as part of patient care
Medical School Faculty

- Most can still see representatives: some limited within the clinic to certain locations (HIPPA)
- Some can accept samples and coupons
- Some can accept lunches or snacks
- Can participate in pharmaceutical research
- Can participate in investigator initiated research
Dermatology Residents

- Some can see pharmaceutical representatives
- Some can attend industry sponsored dinners
- Challenge for residents who cannot see representatives:
  - do not learn about new (or even older) products
  - may prescribe only from a narrow formulary during training
Changes in Industry: Dermatology

- Fewer companies overall
- Greater consolidation
- Challenge to initiate research
Challenges in Daily Practice Related to Industry

- Using Brand Name Products:
  - Often third tier on pharmacy benefit plan
  - Use may impact a physician’s profile on:
    - Blue Cross/ United/ Aetna/ Cigna

- Not using Brand Name Products:
  - Less than optimized outcome for patients
  - Fewer new and innovative new products in future
Challenges in Daily Practice Related to Industry

- Most patients do NOT understand their insurance policy with regard to coverage
- Most patients view the ability to prescribe a given medication totally within the physician’s control
Industry: High Impact on Dermatology

- Innovations:
  - Oral Retinoids
  - Biologics
  - Acne Medications
  - Atopic Dermatitis Medications
  - Antifungals
Industry: High Impact on Dermatology

- Research: expanded opportunities for basic science and clinical trials
- Industry listens to and acts on our observations:
  - 5 Fluorouracil
  - Imiquimod
  - Cyclosporin
  - Botox
  - Latisse
  - Propranolol
Industry: High Impact on Dermatology

- Changed the practice of Dermatology more than any other interface
- Improved the lives of our patients and their families
Where we can become stronger together

- Increased collaborative discussions and efforts
- View WDS as a portal for collaboration
- Consider Initiation of:
  - Research Modules
  - Leadership Opportunities
Thanks

- Special thanks to all in Industry who partner with the WDS
- WDS values these relationships
- WDS hopes to enhance and expand the value of interchange between our organization and its industry partners